BESIFLOXACIN THE FOURTH GENERATION FLUOROQUINOLONE: A REVIEW
Besifloxacin is fourth generation ophthalmic fluoroquinolone of synthetic origin, it was approved by the United States Food and Drug Administration (USFDA) in May 2009 for the treatment of bacterial conjunctivitis. It is only fluoroquinolone that has not been studied for systemic use; it was sold first in United States of America (USA) under the trade name of BesivanceÂ® ophthalmic suspension 0.6% formulated with DuraciteÂ®technology. This review article provides an overview of the pharmacology, efficacy and tolerability of besifloxacin suspension in the treatment of bacterial conjunctivitis, along with their different analytical techniques.Besifloxacin is a broad spectrum antibiotic active against ocular bacterial pathogen Streptococcus pneumonia, Staphylococcus aureus, Staphylococcus epidermidis, Haemophilus influenza, Moraxella catarrhalis and Corynebacterium spp.Conjunctival concentration of besifloxacin was reported and found to be Cmax- 62.79Âµg/ml, AUC0-t -5569min.Âµg/ml, MIC90 <0.06-4Âµg/ml after single dose of besifloxacin ophthalmic suspension 0.6% in rabbit. In two randomised, double masked vehicle- control trial study reported the besifloxacin ophthalmic suspension was well tolerated and efficacious than vehicles.Besifloxacin was found to be well tolerated in clinical trial however common adverse effects were blurred vision (2.1%), bacterial conjunctivitis (1.8%), eye pain (1.5%) and non-specific bacterial conjunctivitis. Besifloxacin 0.6% ophthalmic suspension was reported to the well tolerated and efficacious in the treatment of bacterial conjunctivitis.There were several methods of analysis like UV, HPLC and microbiological for the quantification of besifloxacin.Keywords: Besifloxacin, Moxifloxacin, Gatifloxacin, Bacterial conjunctivitis, HPLC Pharmacokinetic
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).